Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Black Diamond Therapeutics (BDTX) Accounts Payables (2018 - 2025)

Black Diamond Therapeutics' Accounts Payables history spans 6 years, with the latest figure at $579000.0 for Q4 2025.

  • For Q4 2025, Accounts Payables fell 85.55% year-over-year to $579000.0; the TTM value through Dec 2025 reached $579000.0, down 85.55%, while the annual FY2025 figure was $579000.0, 85.55% down from the prior year.
  • Accounts Payables reached $579000.0 in Q4 2025 per BDTX's latest filing, down from $975000.0 in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $5.0 million in Q2 2021 to a low of $579000.0 in Q4 2025.
  • Average Accounts Payables over 3 years is $2.5 million, with a median of $2.0 million recorded in 2024.
  • Peak YoY movement for Accounts Payables: soared 11077.78% in 2021, then tumbled 85.55% in 2025.
  • A 3-year view of Accounts Payables shows it stood at $4.9 million in 2021, then dropped by 17.53% to $4.0 million in 2024, then crashed by 85.55% to $579000.0 in 2025.
  • Per Business Quant, the three most recent readings for BDTX's Accounts Payables are $579000.0 (Q4 2025), $975000.0 (Q3 2025), and $771000.0 (Q2 2025).